Overview

Recludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets.  Our platform approach integrates custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. 

Recludix is employing this platform approach first in the development of SH2 domain inhibitors for the treatment of cancer and inflammatory disease. SH2 domains have been recognized as playing a key role in disease signaling pathways for over 30 years; however, scientists had been unable to target them for the development of therapeutics. Recludix has developed a novel SH2-focused platform that integrates new chemical approaches and technologies, including custom SH2 domain libraries and assays, to develop precision small molecule medicines.

The company’s most advanced programs are focused on Signal Transducer and Activator of Transcription (STAT) proteins found within the Janus Kinase (JAK)/STAT signaling pathway. Abnormal STAT activation is found in numerous cancer types, such as multiple leukemias and lymphomas, as well as inflammatory diseases, such as rheumatoid arthritis, asthma, atopic dermatitis inflammatory bowel disease, and others. Additionally, the company is advancing a program with a different SH2 domain target that also plays a significant role in various diseases.

Our Team Members

Nancy Whiting, Pharm.D.

Chief Executive Officer

Nancy is the Chief Executive Officer of Recludix and has an established track record in all phases of drug development. Nancy is a 15-year veteran of Seagen, formerly Seattle Genetics. Most recently, she was the Executive Vice President of Corporate Strategy, where she had the broad remit of corporate strategy and planning, strategic alliances and partnerships, investor relations, corporate communications and information technologies. She previously served as Executive Vice President of Late Stage Development, Senior Vice President of Clinical Development and Medical Affairs, and Head of Experimental Medicine. During her tenure at Seagen, Nancy played a central role in the development and regulatory approval of ADCETRIS for lymphoma, PADCEV for bladder cancer, TUKYSA for breast cancer, TIVDAK for cervical cancer, and several other pipeline compounds. Prior to transitioning to the pharmaceutical industry, Dr. Whiting practiced as a Clinical Oncology Pharmacist at the Seattle Cancer Care Alliance. Dr. Whiting completed her undergraduate training at the University of British Columbia and received her Pharm.D. from the University of Washington. She also completed a residency in clinical pharmacy practice at Vancouver General Hospital. Dr. Whiting is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the European Society of Medical Oncology. She serves on the Board of Directors of Caribou BioSciences.

Brian Hodous, Ph.D.

Vice President of Chemistry

Brian Hodous is a co-founder of Recludix Pharma and serves as Vice President of Chemistry. Dr. Hodous has nearly 20 years of experience in drug discovery and preclinical development. He spent his career at several large and start-up biotechnology companies, where he contributed to the discovery of multiple clinical molecules and one approved drug, set company strategy and implemented initiatives to foster team/culture building. Dr. Hodous was most recently the Head of Chemistry at Accent Therapeutics responsible for drug discovery strategy and chemical matter identification/optimization in the emerging area of RNA-modifying protein biology. From 2011 to 2017, Dr. Hodous was at Blueprint Medicines where he co-led the advancement of their proprietary kinase inhibitor library strategy and design efforts. During his tenure at Blueprint, he was a co-inventor and co-program lead for: AYVAKIT (avapritinib), a potent, selective KIT/PDGFR inhibitor approved for the treatment of patients with PDGFRa mutant GIST and patients with advanced systemic mastocytosis; Fisogatinib, a potent, selective, covalent inhibitor of FGFR4 in clinical trials for patients with hepatocellular carcinoma; and IPN60130 (out-licensed to Ipsen Biopharmaceuticals, formerly BLU-782), a potent, selective inhibitor of ALK2 kinase that is currently in Phase 2 clinical trials for the treatment of patients with the rare genetic disease, fibrodysplasia ossificans progressiva.  While at EMD Serono, he co-invented and co-led the development of evobrutinib, a highly potent, selective, covalent BTK inhibitor that is currently in Phase 3 clinical trials for multiple sclerosis. From 2002-2008, Dr. Hodous was at Amgen where he co-invented AMG-900, a pan-Aurora kinase inhibitor that went into Phase 1 clinical trials for oncology indications. Dr. Hodous holds a Ph.D. in Organic Chemistry from MIT.

Board of Directors

Nancy is the Chief Executive Officer of Recludix and has an established track record in all phases of drug development. Nancy is a 15-year veteran of Seagen, formerly Seattle Genetics. Most recently, she was the Executive Vice President of Corporate Strategy, where she had the broad remit of corporate strategy and planning, strategic alliances and partnerships, investor relations, corporate communications and information technologies. She previously served as Executive Vice President of Late Stage Development, Senior Vice President of Clinical Development and Medical Affairs, and Head of Experimental Medicine. During her tenure at Seagen, Nancy played a central role in the development and regulatory approval of ADCETRIS for lymphoma, PADCEV for bladder cancer, TUKYSA for breast cancer, TIVDAK for cervical cancer, and several other pipeline compounds. Prior to transitioning to the pharmaceutical industry, Dr. Whiting practiced as a Clinical Oncology Pharmacist at the Seattle Cancer Care Alliance. Dr. Whiting completed her undergraduate training at the University of British Columbia and received her Pharm.D. from the University of Washington. She also completed a residency in clinical pharmacy practice at Vancouver General Hospital. Dr. Whiting is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the European Society of Medical Oncology. She serves on the Board of Directors of Caribou BioSciences.

Dr. Lydon is a co-founder and Chairman of Recludix and has served as a member of our board of directors and as a scientific advisor since 2019. Dr. Lydon is also a scientific founder of Blueprint Medicines and has served as a member of their board of directors since April 2011. Dr. Lydon is a co-founder of AnaptysBio Inc. and served as a scientific advisor and member of its board of directors between 2006 and 2019. From 2003 to 2009, he served as a scientific advisor and member of the board of directors of Ambit Biosciences Corp., a biopharmaceutical company. From 2000 to 2002, Dr. Lydon served as vice president, small molecule drug discovery, at Amgen, Inc., or Amgen. Prior to joining Amgen, Dr. Lydon founded Kinetix Pharmaceuticals, Inc., or Kinetix, a biotechnology company focused on the discovery and development of selective protein kinase inhibitors, which was acquired by Amgen in 2000, and served as Kinetix’s chief executive officer and as a member of its board of directors. Prior to founding Kinetix, he worked for Ciba-Giegy AG (now Novartis AG) where he was responsible for the tyrosine protein kinase program, including the discovery and preclinical development of imatinib. Dr. Lydon, has been awarded the Lasker-DeBakey Clinical Medical Research Award, the Kettering Price from the General Motors Cancer Research Foundation and the Japan Prize for his role in the development of imatinib. Dr. Lydon received a B.S. in biochemistry and zoology from the University of Leeds, England, and received a Ph.D. in biochemistry from the Medical Sciences Institute, University of Dundee, Scotland.

Dr. Gallagher is a Venture Partner at NEA. Dr. Gallagher is a proven entrepreneur, operator and more recently investor with over 30 years of experience in commercial, drug development and business development roles. Prior to joining NEA she was a Venture Partner with Frazier Healthcare.  Since 2011, she has served as an independent director on multiple boards of biopharma companies. From 2008-2011, Dr. Gallagher was president and CEO of Calistoga Pharmaceuticals which developed the first-in-class therapeutic now marketed by Gilead as ZYDELIG.  Prior to Calistoga Pharmaceuticals, she had a long career with various operating roles at both large and small biopharma companies.  She also serves as a director at AtaraBio, Certara, Chromacode, PIONYR Immunotherapeutics, Qpex BioPharma, T Rex Bio, and Turning Point Therapeutics.

Dr. Seidenberg is a founding managing director of Westlake Village BioPartners and a general partner at Kleiner Perkins, a leading venture capital firm. A longtime life sciences investor, she has incubated-invested in greater than 30 biotech companies.

Dr. Seidenberg has a demonstrated ability to identify and accelerate medically meaningful molecules through development. Her expertise is grounded in her significant senior level industry experience with leadership roles at Amgen, Bristol-Myers Squibb and Merck Research Laboratories. Most recently, at Amgen, Dr. Seidenberg was chief medical officer and head of global development.

Dr. Seidenberg holds a Bachelor of Science degree in biology and anthropology from Barnard College and attended medical school at the University of Miami School of Medicine. She completed her medical residency at Johns Hopkins University and the George Washington University, and Fellowship at the National Institutes of Health.

Named by Time as one of the 50 most influential people in healthcare in 2018, Dr. Harper has helped bring well over a dozen novel therapies to patients during his career. In areas as diverse as oncology, osteoporosis, cardiovascular disease and migraine, Dr. Harper’s passion for science and medicine has benefited millions of patients worldwide.

Dr. Harper brings a rare breadth of experience in both basic research and as a practicing physician. He has led a wide range of clinical research programs, from early translational trials to global outcomes studies. As co-founding managing director of Westlake Village BioPartners, Dr. Harper identifies promising new therapies and technologies and builds companies to address significant unmet medical needs.

From 2002 to 2018, Dr. Harper worked for Amgen, rising to become head of R&D in 2012, where he managed investments of more than $3.5 billion annually, applying breakthroughs in science to address some of society’s biggest health challenges.

Dr. Ratcliffe is the Head of Biotechnology at Access Industries. He was previously Managing Director at New Leaf Venture Partners, where he focused on investing in therapeutic and therapeutic platform companies for 10 years. Prior to joining New Leaf, Dr. Ratcliffe was Senior Vice President and Development Head for Neuroscience, as well as Worldwide Head of Clinical Research and Development at Pfizer, where he spent a total of 12 years. Dr. Ratcliffe received his medical degree and Ph.D. in Immunology from the University of Cape Town and his M.B.A. from the University of Michigan. He completed his internal medicine training and fellowship in Immunology at Groote Schuur Hospital and associated teaching hospitals in Cape Town, South Africa.

Dr. McAviney is a Partner at NEA focused on biopharma investments. Prior to NEA, Dr. McAviney was a Principal at F-Prime Capital Partners. During his five years at F-Prime, he was responsible for closing investments in more than 20 private biopharma companies, and served on the board of more than 10 portfolio companies. Prior to F-Prime, he was a management consultant in the health and life sciences practice at Oliver Wyman, a biotech equity research analyst at Robert W. Baird, and a healthcare investment banker at JP Morgan. Dr. McAviney also conducted lipid metabolism research at the National Institute of Diabetes, Digestive and Kidney Disorders.

Dr. McAviney received a BA with Honors in Biological Sciences from the University of Chicago, an MD from the University of Illinois, and an MBA from the University of Chicago Booth School of Business.

Investors